Severe Rhabdomyolysis Associated with Simvastatin and Role of Ciprofloxacin and Amlodipine Coadministration
Simvastatin is among the most commonly used prescription medications for cholesterol reduction and the most common statin-related adverse drug reaction is skeletal muscle toxicity. Multiple factors have been shown to influence simvastatin-induced myopathy. In addition to age, gender, ethnicity, gene...
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Hindawi Publishing Corporation
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391689/ |
| id |
pubmed-4391689 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-43916892015-04-16 Severe Rhabdomyolysis Associated with Simvastatin and Role of Ciprofloxacin and Amlodipine Coadministration De Schryver, Nicolas Wittebole, Xavier Van den Bergh, Peter Haufroid, Vincent Goffin, Eric Hantson, Philippe Case Report Simvastatin is among the most commonly used prescription medications for cholesterol reduction and the most common statin-related adverse drug reaction is skeletal muscle toxicity. Multiple factors have been shown to influence simvastatin-induced myopathy. In addition to age, gender, ethnicity, genetic predisposition, and dose, drug-drug interactions play a major role. This is particularly true for drugs that are extensively metabolized by cytochrome P450 (CYP)3A4. We describe a particularly severe case of rhabdomyolysis after the introduction of ciprofloxacin, a weak CYP3A4 inhibitor, in a patient who previously tolerated the simvastatin-amlodipine combination. Hindawi Publishing Corporation 2015 2015-03-26 /pmc/articles/PMC4391689/ /pubmed/25883814 http://dx.doi.org/10.1155/2015/761393 Text en Copyright © 2015 Nicolas De Schryver et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
De Schryver, Nicolas Wittebole, Xavier Van den Bergh, Peter Haufroid, Vincent Goffin, Eric Hantson, Philippe |
| spellingShingle |
De Schryver, Nicolas Wittebole, Xavier Van den Bergh, Peter Haufroid, Vincent Goffin, Eric Hantson, Philippe Severe Rhabdomyolysis Associated with Simvastatin and Role of Ciprofloxacin and Amlodipine Coadministration |
| author_facet |
De Schryver, Nicolas Wittebole, Xavier Van den Bergh, Peter Haufroid, Vincent Goffin, Eric Hantson, Philippe |
| author_sort |
De Schryver, Nicolas |
| title |
Severe Rhabdomyolysis Associated with Simvastatin and Role of
Ciprofloxacin and Amlodipine Coadministration |
| title_short |
Severe Rhabdomyolysis Associated with Simvastatin and Role of
Ciprofloxacin and Amlodipine Coadministration |
| title_full |
Severe Rhabdomyolysis Associated with Simvastatin and Role of
Ciprofloxacin and Amlodipine Coadministration |
| title_fullStr |
Severe Rhabdomyolysis Associated with Simvastatin and Role of
Ciprofloxacin and Amlodipine Coadministration |
| title_full_unstemmed |
Severe Rhabdomyolysis Associated with Simvastatin and Role of
Ciprofloxacin and Amlodipine Coadministration |
| title_sort |
severe rhabdomyolysis associated with simvastatin and role of
ciprofloxacin and amlodipine coadministration |
| description |
Simvastatin is among the most commonly used prescription medications for cholesterol reduction and the most common statin-related adverse drug reaction is skeletal muscle toxicity. Multiple factors have been shown to influence simvastatin-induced myopathy. In addition to age, gender, ethnicity, genetic predisposition, and dose, drug-drug interactions play a major role. This is particularly true for drugs that are extensively metabolized by cytochrome P450 (CYP)3A4. We describe a particularly severe case of rhabdomyolysis after the introduction of ciprofloxacin, a weak CYP3A4 inhibitor, in a patient who previously tolerated the simvastatin-amlodipine combination. |
| publisher |
Hindawi Publishing Corporation |
| publishDate |
2015 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391689/ |
| _version_ |
1613209717729918976 |